Physician profile
Ronika Nirankari Newbold
NPI 1538728886
$2,136.43
in general payments reported to CMS, 2019-2025
15 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.03 · 2020: $15.70 · 2021: $35.05 · 2023: $590 · 2024: $1,043 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $544.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $519.51 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $279.11 | 2023-2025 | |
| Pfizer INC. | $236.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $213.63 | 2023-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $127.61 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Integra Lifesciences Corporation | $41.30 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Exact Sciences Corporation | $40.40 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $37.76 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $20.88 | 2021 | |
| Corcept Therapeutics | $19.02 | 2025 | Korlym |
| Amgen INC. | $15.70 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.17 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.28 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronika Newbold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.